

# We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

4,800

Open access books available

122,000

International authors and editors

135M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index  
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?  
Contact [book.department@intechopen.com](mailto:book.department@intechopen.com)

Numbers displayed above are based on latest data collected.

For more information visit [www.intechopen.com](http://www.intechopen.com)



# Gene Therapy of Hematopoietic and Immune Systems: Current State and Perspectives

Maria Savvateeva<sup>1</sup>, Fedor Rozov<sup>1,2</sup> and Alexander Belyavsky<sup>1</sup>

<sup>1</sup>*Engelhardt Institute of Molecular Biology, Russian Academy of Sciences*

<sup>2</sup>*University of Oslo, Centre for Medical Studies Russia, Moscow  
Russian Federation*

## 1. Introduction

Hematopoietic stem cells (HSCs) present arguably the best entry point for gene therapy of hematopoietic and immune systems since genetically modified HSCs are long-lived and would eventually transfer the therapeutic constructs to all their descendants. However, gene therapy via HSCs, although conceptually simple, has proven to be a technically formidable problem that has yet to be solved successfully. Despite overtly positive results obtained in gene therapy experiments performed with mouse and larger animal models, these achievements did not translate into clinically acceptable outcomes for non-human primates and human patients, with exception of a few specific disease instances where a therapeutic gene brought about significant survival advantages to transduced cells (Cavazzana-Calvo et al., 2000, Schmidt et al, 2003). Major differences between outcomes of conceptually similar experiments in mice and primates underscore the notion that the fundamental principles governing functioning of hematopoietic system in small short-lived vs. larger long-lived animals differ significantly. Low degree of chimerism obtained in experiments with primates and humans is likely a result of intrinsically low efficiency of viral transduction of long-term repopulating (LTR) HSCs coupled with subsequent massive silencing of integrated constructs (Ellis, 2005; Horn et al, 2002). One may hypothesize that this situation reflects a better protection of hematopoietic system from external influences, in particular invasion of foreign genetic material, in longer-living animals.

However, our deepening knowledge of molecular mechanisms underlying functioning of HSCs within the organism provides hints as to what strategies may lead to the development of the efficient gene therapy via HSCs; some of these strategies are discussed below.

## 2. Improvements of vectors and ex vivo HSC transduction protocols

Numerous studies indicate that lentiviral vectors that are capable of transducing non-dividing cells may represent a more promising tool for introduction of genetic material into HSCs compared to retroviral vectors (Uchida et al, 1998, Case et al., 1999). This may be attributed to a largely quiescent nature of LTR HSCs, especially in larger animals (Cheshier et al., 1999, Shepherd et al., 2007). Since even lentiviral vectors transduce more efficiently dividing cells than quiescent ones (Trobridge et al., 2004), the current transduction protocols relied until recently on the use of culture conditions that induced entry of HSCs into cell

cycle but incidentally failed to maintain their stem cell status (Bunting et al., 1999). This situation seems to have been ameliorated after introduction of transduction protocols that rely on the use of serum-free media that lack factors inducing SC differentiation (Mostoslavsky et al., 2005) and novel growth factors that better preserve cell stemness (Zhang C et al., 2008). It remains yet to see whether these improvements are sufficient to significantly increase the efficiency of HSC gene therapy in clinical settings.

### **3. Selection of genetically modified HSCs in vivo: Negative selection**

As current efficiency of transduction of human LTR HSCs with viral vectors appears to be quite low and there are no clinically proven protocols for expansion of these cells *ex vivo*, the most promising solution at hand to this problem is an *in vivo* selection of modified cells after their transduction and re-transplantation back to a patient. Conceptually, one might distinguish negative and positive *in vivo* selection strategies. The first one can be defined as a strategy that is aimed at elimination of stem and progenitor cells that do not bear integrated functional constructs. Positive selection implies a strategy that does not target the construct-negative stem cells but rather provides selective survival and growth advantage to the cells that bear the inserted construct. The negative selection gains presently much of attention and seems to be better poised for a clinical advancement in the near future. Arguably, the most promising and advanced variant of negative selection is based on the use of O6-MGMT as a selection marker and various alkylating compounds as selection agents (Davis et al., 2000, Ragg et al., 2000). Using this approach and multiple rounds of selection *in vivo*, overall peripheral blood chimerism has been driven in mice and larger animal models to levels higher than 75%. However, the clinical applicability of this technique is as yet unclear, as recent experiments performed by two research teams with non-human primates using MGMT-mediated selection produced rather conflicting results. One team demonstrated successful implementation of this strategy in monkeys, although with selection efficiencies and chimerism rates highly variable between individual animals (Beard et al., 2010), whereas another team reported a rather negligible increase in chimerism rates upon selection *in vivo* (Larochelle et al., 2009).

Various implementations of negative selection strategy are listed in the Table 1.

### **4. Selection of genetically modified HSCs in vivo: Positive selection**

Ongoing studies of the mechanisms controlling HSC self-maintenance and commitment continue to identify novel factors that bring about HSC expansion *in vivo* when over-expressed. A less than exhaustive set of these factors is listed in the Table 2. Arguably, the most extensively studied gene with such properties is the homeobox transcription factor HoxB4. Forced expression of HoxB4 in murine HSCs induces remarkable *ex vivo* and *in vivo* cell expansion without compromising their differentiation or inducing leukemic transformation (Sauvageau et al., 1995, Antonchuk et al., 2002). Similar effects were obtained using recombinant TAT-HOXB4 protein (Krosl et al., 2003). In some reports, HoxB4 and negative selection marker MGMT were used together to further increase percentage of modified HSCs (Chinnasamy et al., 2005). However, attempts to use HoxB4 for positive selection of HSCs in larger animals were much less successful, with a major expansion of short-term repopulating cells only (Zhang X et al., 2006). Besides, a significant number of leukemia occurrences apparently related to unregulated expression of HoxB4 were observed in these animals (Zhang X et al., 2008).

Selective marker	Selecting agent	Mode of action	References
O6-MGMT	BCNU, TMZ, other alkylating agents	MGMT protein functions to repair alkylated DNA caused by chemotherapeutic agents like BCNU or TMZ	Sawai et al, 2001; Zielske et al, 2003
Thymidylate synthase	5-fluorouracil (5-FU) 5-fluorodeoxyuridine (5-FUdR)	Drug-resistant TS can protect bone marrow cells from 5-fluorouracil (5-FU) and related fluoropyrimidines that induce cessation of DNA and RNA synthesis, and subsequent cell death.	Bielas et al, 2009
Tyr22DHFR	Methotrexate	MTX acts on highly proliferative cells, blocking DNA synthesis through competitive inhibition of DHFR. Drug resistant dihydrofolate reductase such as Tyr22 (Tyr22DHFR) has the potential to selectively increase engraftment of gene-modified human hematopoietic cells	Gori et al, 2010
Multidrug resistance gene-1 (MDR)	Taxol, Paclitaxel	Overexpression of the multidrug resistance gene MDR1 in bone marrow cells results in protection from hematopoietic toxicity from chemotherapy drugs that are substrates for the MDR1 drug efflux pump	Cowan et al, 1999

Table 1. Strategies for negative selection of genetically modified HSC

Some other members of the HOX family, either alone or fused with specific cellular partners, are also able to induce expansion of hematopoietic progenitors in mice. Of particular importance is a fusion gene NUP98-HoxA10, which has a remarkable ability of multi-log expansion of murine repopulating cells *ex vivo*, exceeding that of HoxB4 (Ohta et al., 2007; Watts et al., 2011).

Recently, the powerful effect of overexpression of early acting transcription factor SALL4 on *ex vivo* expansion of human hematopoietic cells capable of long-term repopulation of NOD/SCID mice was demonstrated (Aguila et al., 2011). Significant *ex vivo* expansion could be also achieved using recombinant TAT-SALL4B protein.

There are at least a dozen of other genes that, when overexpressed, induce significant expansion of HSCs in mice *in vivo*. One of the most interesting groups of such factors are epigenetic regulators. Of particular interest is Bmi1, a member of Polycomb group, which is involved in regulation of maintenance of various adult stem cell types. Inactivation of Bmi1

leads to defect in HSC self-renewal (Park et al., 2003), whereas its enforced expression results a striking *ex vivo* expansion of multipotential progenitors and marked augmentation of HSC repopulating capacity *in vivo* (Iwama et al., 2004). In addition, enforced expression of Bmi1 in human CD34-positive cells leads to the *ex vivo* expansion of NOD/SCID repopulating cells (Rizo et al., 2008). Another Polycomb group gene that potentially could be used for positive selection is Ezh2; upon overexpression, it prevents HSC exhaustion (Kamminga et al., 2006). Forced expression of yet another epigenetic regulator, histone demethylase Fbxl10/Jhdm1b in HSCs abolishes exhaustion of the LTR HSCs following serial transplantation. This property of Ezh2 and Fbxl10/Jhdm1b makes them especially appropriate for schemes combining positive and negative selection since the latter one places very significant stress on hematopoietic system.

Another group of genes that might be used for positive selection are those that are frequently activated in predominant hematopoietic cell clones arising after retro- or lentiviral transduction, and are likely therefore to act as factors inducing *in vivo* expansion of these clones. The most prominent among such genes are MDS1/Evi-1 (Sellers et al., 2010; Métais & Dunbar, 2008), PRDM16 (Du et al., 2005; Ott et al., 2006) HMGA2 (Wang et al., 2010; Cavazzana-Calvo et al., 2010) and LMO2 (McCormack et al., 2003; McCormack et al., 2010). As a note of caution, forced expression of these genes may produce undesired effects; for example, expression of Evi-1 was reported to be associated with chromosomal instability (Stein et al., 2010).

In addition to protein factors, micro RNAs also have effect on HSC function and population size. In particular, miR-125a and miR-125b were shown to increase number of HSCs *in vivo* or enhance their repopulation capacity (Guo et al., 2010; Ooi et al., 2010).

Having focused on genes that expand stem cell population, one should not overlook another group of genes that exert an opposite effect, namely negative influence on HSC pool size. Thanks to RNA interference technology, suppression of gene expression in various cell types nowadays is nearly as simple as overexpression. If gene knockout or knockdown results in expansion of stem cell population, this property may potentially be used for positive selection. Among genes of interest in this respect are C/EBP alpha, Lnk and Nur77, to name a few. C/EBP alpha-deficient hematopoietic stem cells (HSCs) are hyperproliferative, have increased expression of Bmi-1 and enhanced competitive repopulating activity (Zhang et al., 2004; Heath et al., 2004). Inactivation of Lnk, inhibitory adaptor protein, leads to an expanded HSC pool with enhanced self-renewal (Bersenev et al., 2008). Mice with inactivation of both Nor-1 and Nur77 have abnormal expansion of HSCs and myeloid progenitors and develop lethal acute myeloid leukemia (AML).

Regardless of what gene is being used for positive selection, it is clear that its constitutive expression would eliminate one or more of the negative growth controls imposed on HSCs by organism, and thus increase risks of neoplastic transformation. Therefore, any clinically acceptable protocol for gene therapy using positive selection of transduced HSCs should be based on transient, tightly regulated gene expression. Given that positive selection, if correctly implemented, promises to provide significant advantages over negative selection schemes, further research into creation of robustly regulated expression systems for positive selection in HSCs seem to be fully warranted.



Gene	Observed effects	References
HOXB4	Overexpression of HoxB4 induces significant ex vivo and in vivo expansion of murine long-term repopulating HSCs.	Antonchuk et al., 2002; Sauvageau et al., 1995
NUP98-HOXA10	Enforced expression of NUP98-HOXA10 fusion protein results in significant expansion of murine repopulating cells ex vivo exceeding that of HoxB4.	Ohta et al., 2007; Watts et al., 2011
NF-Ya	Murine HSCs overexpressing NF-Ya demonstrate strongly increased in vivo repopulation.	Zhu et al., 2005
Bmi1	Enforced expression of Bmi1 leads to striking ex vivo expansion of multipotential progenitors and marked augmentation of HSC repopulating capacity in vivo.	Iwama et al., 2004; Rizo et al., 2008
Ezh2	Overexpression prevents exhaustion of long-term repopulating HSCs.	Kamminga et al., 2006
Fbxl10/Jhdm1b	Same as above.	Konuma et al., 2011
Jab1	Mice with Jab1 overexpression have expanded HSC pool and develop a myeloproliferative disease.	Mori et al., 2008
HMGA2	Frequently found in the vicinity of integrated constructs in gene therapy trials; HMGA2-expressing cells have growth advantage in competitive repopulation and serial transplantation.	Cavazzana-Calvo et al., 2010; Ikeda et al., 2011; Wang et al., 2010
Evi-1	Frequently found in the vicinity of integrated constructs in gene therapy trials.	Métais & Dunbar, 2008; Sellers et al., 2010
PRDM16	Frequently found in the vicinity of integrated constructs in gene therapy trials.	Du et al., 2005; Ott et al., 2006
Sall4	Enforced expression results in ex vivo expansion of long-term NOD/SCID repopulating cells.	Aguila et al., 2011
MicroRNAs miR-125a, miR-125b	Forced expression of miR-125a was capable of increasing the number of HSCs cells several-fold. Overexpression of miR-125b enhances HSC function, as judged by serial transplantation.	Guo et al., 2010; Ooi et al., 2010
Lnk	Mice with Lnk inactivation have an expanded HSC pool with enhanced self-renewal.	Bersenev et al., 2008
Nur77/NR4A1 & Nor-1/NR4A3	Mice with inactivation of both Nor-1 and Nur77 have abnormal expansion of HSCs and myeloid progenitors and develop lethal acute myeloid leukemia.	Mullican et al., 2007
C/EBP $\alpha$	C/EBP alpha-deficient HSCs are hyperproliferative and have enhanced competitive repopulating activity.	Heath et al., 2004; Zhang P et al. 2004;
Latexin	Mouse strains expressing lower latexin levels have increased numbers of HSCs.	Liang et al., 2007

Table 2. Genes affecting in vivo expansion of HSCs

## 5. Expansion and selection of genetically modified HSCs ex vivo

Although much hope is currently invested into various schemes aimed at *in vivo* selection of gene-modified HSCs, a substantially simpler and arguably more elegant solution may be achieved if protocols for long-term culture and robust *ex vivo* expansion of HSCs could be developed. Very significant expansion of HSCs that occurs during embryonic development indicates that this might be eventually possible.

Over the last two decades, quite a few HSC culture protocols have been developed. The earlier established conditions involved cultivation in the presence of serum and cocktail of “classical” cytokines including SCF, IL3, IL6, FLT3L and TPO. Since bovine serum apparently contains factors that induce differentiation and/or apoptosis of HSCs, recent, more advanced protocols have been developed, which use defined, serum-free conditions that offer better reproducibility and minimize rapid loss of long-term repopulating HSCs during *ex vivo* culture and transduction with lenti- and retroviral vectors (Mostoslavsky et al., 2005).

In addition to classical cytokines, a number of new growth factors that have pronounced effect on HSC maintenance and expansion were identified in the last years. Among the most important are FGF1 (de Haan et al., 2003), IGFBP2 (Huynh et al., 2008), and several members of angiopoietin-like family, in particular Angptl3 and 5 (Zhang et al., 2006).

Several major signaling pathways figuring prominently during embryonic development, in particular during specification of hematopoietic lineage, were shown to be important for adult HSC biology. Among those, Notch and Wnt pathways are currently considered as of the most immediate interest as far as HSC-niche interactions and *ex vivo* expansion are concerned. Stem and progenitor pool-enhancing properties of Notch signaling were demonstrated initially using constitutive Notch1 signaling in murine hematopoietic cells, which produced immortalized, cytokine-dependent stem cell-like cells (Varnum-Finney et al., 2000), and constitutive Notch4 signaling in human cord blood cells, which resulted in significant increase in cells repopulating immunodeficient mice (Vercauteren & Sutherland, 2004). Later on, culture of human CD34<sup>+</sup> precursors with the immobilized Notch ligand Delta1 and cytokines was shown to result in a substantial increase in NOD/SCID-repopulating cells (Delaney et al., 2010); similar results were obtained for mouse cells with immobilized Jagged1 ligand (Toda et al., 2011).

As for Wnt signaling, initial studies indicated that overexpression of activated beta-catenin expanded the pool of HSCs in long-term cultures as judged by both phenotype and function. Wnt3a protein induced self-renewal of haematopoietic stem cells, whereas ectopic expression of inhibitors of the Wnt signalling pathway led to suppression of HSC growth *in vitro* and reduced reconstitution *in vivo* (Reya et al., 2003; Willert et al., 2003). Later publications demonstrated, though, that inactivation of the beta-catenin gene in bone marrow progenitors does not impair their ability to self-renew and reconstitute all hematopoietic lineages (Cobas et al., 2004), whereas activation of beta-catenin enforced cell cycle entry of hematopoietic stem cells, thus leading to exhaustion of the long-term stem cell pool (Sheller et al., 2006). Some recent studies demonstrate that it is the non-canonical Wnt signaling promoted by Wnt5a rather than the canonical one, that supports maintenance of competitive repopulating murine HSCs in culture (Buckley et al., 2011; Nemeth et al., 2007).

Yet another line of evidence indicates that activation of beta-catenin in the niche components rather than in HSCs may produce support of LTR cells *ex vivo* (Nemeth et al., 2009). Currently, there is little doubt that Wnt signaling plays important role in HSC biology, but the issue is apparently more complex than was implied by initial publications and remains highly controversial.

Other embryonic signaling pathways also might be exploited in HSC culture. Morphogens of the hedgehog family, namely Sonic and Indian hedgehogs, are able to support *ex vivo* expansion of human NOD/SCID repopulating cells (Bhardwaj et al., 2001; Kobune et al., 2004), despite the fact that *in vivo* Hedgehog signaling seems to not be necessary for adult murine hematopoietic stem cell function (Hofmann et al., 2009). BMP4, a member of BMP superfamily, is a critical component of the hematopoietic niche that regulates both HSC number and function (Goldman et al., 2009), and is able to expand NOD/SCID-repopulating cells in culture (Hutton et al., 2006).

In addition to the use of secreted proteins to for *ex vivo* HSC culture, one apparent trend of the last years is the application of low-molecular weight chemicals, in particular agonists or inhibitors of particular intracellular signaling pathways, for *ex vivo* culture. Thus, specific inhibitor of p38 kinase induces self-renewal and *ex vivo* expansion of HSCs as shown by the *in vitro* cobblestone area forming cell assay and serial transplantation (Wang et al., 2011). GSK-3 $\beta$  inhibitors, which stimulate Wnt signaling, were shown to promote engraftment of cultured HSCs (Ko et al., 2011; Trowbridge et al., 2006). Of significant clinical interest is the finding that *ex vivo* treatment with stabilized prostaglandin E2 enhances frequency of both hematopoietic progenitors and long-term repopulating HSCs present as analyzed by competitive transplantation (North et al., 2007). According to other data, only the short-term repopulating HSCs are expanded by this treatment, though (Frisch et al., 2009).

The initial studies demonstrating substantial degree of expansion of HSCs *ex vivo* relied the use of stromal cells as feeder layers (Moore et al., 1997). Based on the substantial progress in identification of HSC niches in bone marrow, there is currently a revival of interest in development of protocols for co-culture of HSC with stromal cell layers (Chou & Lodish, 2010; De Toni et al., 2011). These stromal cells produce a range of factors that significantly improve the maintenance and expansion of HSCs in culture, most likely by mimicking more or less successfully niche conditions. Very prominent components of the HSC niche are cell surface proteins, in particular cell adhesion molecules. The importance of cell-cell interactions was highlighted by the study by Wagner et al., 2007, indicating that maintenance of primitive hematopoietic progenitors by stromal lines is associated with expression of cell adhesion proteins rather than with secretory profiles of these lines. In particular, N-cadherin was shown to be an important component of the osteoblastic HSC niche (Zhang et al., 2003). However, importance of N-cadherin for HSC-niche interactions was later questioned (Kiel et al., 2007), thus rising substantial controversy. In an elegant *in vitro* study Lutolf et al. (2009) have shown that N-cadherin, as well as Wnt3a, are the only proteins among those tested that were capable of supporting self-renewal divisions of HSCs *in vitro*. N-cadherin expression was also shown to be important for maintenance of long-term repopulating cells in culture (Hosokawa et al., 2010). Ability of stromal cell line FMS/PA6-P to support primitive murine hematopoietic cells was found to depend critically on N-CAM expression (Wang et al., 2005). Yet another cell adhesion protein, namely mKirre, plays a prominent role in hematopoietic supportive capacity of OP9 stromal cells (Ueno et al., 2003).



Quite promising developments occur currently in the field of 3-D culture (Yuan et al., 2011; Tan et al., 2010; Miyoshi et al., 2011). Despite a relative paucity of data related to the 3-D culture of HSCs, available publications demonstrate significant advantages of this technique and indicate that in combination with correctly chosen or gene-modified stromal cell layers, 3-D culturing may eventually lead to creation of artificial niche that will be able to support substantial expansion of human HSCs *ex vivo*.

A question of paramount importance for the field is whether specific combinations of soluble factors will be able to attain a bone fide *ex vivo* expansion of HSCs, or this goal can only be achieved if specific cell surface proteins produced by the niche cells are also employed in the process, or perhaps the only way to the eventual success is the use of supporting stromal cell layers for *ex vivo* culture? As a number of molecules that contribute to the maintenance of HSCs *in vitro* and *in vivo* continues to rise, and there is a steady improvement in techniques for culturing HSCs, chances are that within a matter of a few years, key combination(s) of specific factors and modes of their application that can produce robust self-renewal and expansion of human HSC *ex vivo* will be identified. Table 3 provides a list, albeit incomplete, of factors and chemicals that, in addition to “classical” cytokines, are being used for maintenance and expansion of HSCs *ex vivo*.

## 6. Pre-conditioning and transplantation regimens

A common practice in the field of HSC gene therapy is a transduction of HSCs using viral vectors in the *ex vivo* setting. The advantages of this strategy include elimination of non-target transduction events, higher transduction efficiency and better control over the overall process. However, the opposite side of the coin in this case is the necessity for transduced cells to compete with the bone marrow-resident ones, which is likely to lower significantly the degree of chimerism after gene therapy. For efficient repopulation of hematopoietic system with gene-modified HSCs, extensive myeloablative treatments eliminating resident HSCs are usually performed. However, since these treatments are of generalized character and connected with substantial risks of morbidity and mortality, especially for elderly patients, they should preferably be avoided whenever possible. A combination of nonmyeloablative pre-conditioning of the recipient animals with *in vivo* selection strategy can be used to achieve substantial degrees of chimerism (Davis et al., 2000, Zielske et al., 2003). Additional ways to develop more appropriate pretreatment conditions involve the use of molecules that disrupt key signaling pathways within HSCs or niche components thus inducing HSC loss, as was shown for the case of inactivation of c-kit or mpl signaling by neutralizing antibodies (Czechowicz et al., 2007; Yoshihara et al., 2007), and for combined poly(I:C)/5-fluorouracil (5-FU) treatment (Sato et al., 2009). The other approach for nonmyeloablative HSC transplantation is based on disruption of HSC-niche interactions thus aiding in the stem cell mobilization (Chen et al., 2006). This alternative might grow into clinically relevant technique if the efficiency of current protocols for mobilization of HSCs is further improved. The more HSCs are mobilized into circulation and used for viral transduction, the higher is ratio of transduced vs. resident stem cells and better chances to achieve significant engraftment and chimerism of gene-modified cells without resorting to drastic myeloablative regimens. Although current combinations of mobilizing agents (Ramirez et al, 2009) demonstrate much higher mobilization rates than the initially used G-CSF, there is still a long way to go before this strategy may equal or surpass myeloablative pre-conditioning in its efficiency.

Factor	Observed effects	References
FGF1	FGF1 under serum-free conditions stimulates expansion of serially transplantable, long-term repopulating HSCs.	de Haan et al., 2003
Angptl2, 3 and 5	Proteins of angiopoietin-like family provide 20- to 30-fold net expansion of long-term HSCs according to reconstitution analysis.	Zhang C et al., 2006
IGFBP2	IGFBP2 enhances ex vivo expansion of mouse HSCs.	Huynh et al., 2008
IL32	IL-32 significantly induces the proliferation of HSCs in culture.	Moldenhauer et al., 2011
Delta 1, Jagged1 (Notch ligands)	Culturing murine or human cells with surface-immobilized Notch ligands resulted in expansion of primitive hematopoietic population.	Delaney et al., 2010; Toda et al., 2011;
Wnt3a, Wnt10b (Wnt canonical pathway)	Wnt3a protein induces self-renewal of haematopoietic stem cells. Wnt10b enhances growth of hematopoietic precursors.	Willert et al., 2003; Congdon et al., 2010
Wnt5a (Wnt non-canonical pathway)	Wnt5a inhibits canonical Wnt signaling and supports maintenance of competitive repopulating murine HSCs in culture.	Nemeth et. al, 2007; Buckley et al., 2011
Shh, Ihh	Sonic hedgehog and Indian hedgehog support ex vivo expansion of human NOD/SCID repopulating cells.	Bhardwaj et al., 2001; Kobune et al., 2004
Bmp4	BMP4 expands NOD/SCID-repopulating cells in culture.	Hutton et al., 2006
TAT-HOXB4 fusion protein	TAT-HOXB4 protein produces significant ex vivo expansion of murine HSCs.	Krosi et al., 2003
TAT-NF-Ya fusion protein	TAT-NF-Ya protein treatment produces several-fold increase in the percentage of human cells repopulating immunodeficient mice.	Domashenko et al., 2010
TAT-SALL4B fusion protein	TAT-SALL4B fusion protein rapidly expands long-term NOD/SCID repopulating cells.	Aguila et al, 2011
Prostaglandin E2	Ex vivo incubation with PGE2 increases the frequency of long-term repopulating HSCs as measured by competitive transplantation.	North et al., 2007
SB203580	SB203580, specific p38 inhibitor, leads to increase in HSC self-renewal and ex vivo expansion.	Wang et al., 2011
StemRegenin 1	SR1, aryl hydrocarbon receptor antagonist, provides substantial increase in cells engrafting into immunodeficient mice.	Boitano et al., 2010
zVADfmk, zLLYfmk	Cord blood CD34+ cells cultured in presence of zVADfmk or zLLYfmk (inhibitors of caspases and calpains, respectively) have a higher ability for engraftment in NOD/SCID mice.	Imai et al., 2010; Sangeetha et al, 2010;
GSK-3 inhibitors	Pretreatment with GSK-3 inhibitors (BIO or CHIR-911) promotes engraftment and repopulation of ex vivo-expanded HSCs.	Ko et al., 2011; Trowbridge et al., 2006
Rapamycin	HSCs cultured in vitro in the presence of mTOR inhibitor rapamycin demonstrate enhanced engraftment.	Rohrbaugh et al., 2011
Copper helators	Copper chelator tetraethylenepentamine increases long-term ex vivo expansion and engraftment capabilities of blood progenitors.	Peled et al., 2004
N-cadherin	N-cadherin expression on stromal cells is important for maintenance of long-term repopulating cells in culture.	Hosokawa et al., 2010
N-CAM	N-CAM expression on stromal cells supports primitive murine hematopoietic cells.	Wang et al., 2005
mKirre	mKirre is responsible for hematopoietic supportive capacity of OP9 stromal cells.	Ueno et al., 2003

Table 3. Proteins and compounds affecting ex vivo maintenance and expansion of HSCs ("classical" cytokines not listed)

There are reports indicating that the engraftment of gene-modified stem cells might be significantly improved by their direct intra-bone transplantation (Mazurier et al., 2003). As irradiation commonly used for preconditioning also damages hematopoietic niche, in particular mesenchymal stem cells, HSC co-transplantation with MSCs was tested and showed promising results (Masuda et al., 2009).

Even a more radical departure from the accepted strategies for HSCs would be in situ transduction of HSCs using systemic or intra-bone delivery of viral vectors (McCauslin et al., 2003, Pan, 2009). Currently, this is a rather hypothetical approach due to serious safety concerns connected with potential off-target modifications of non-hematopoietic cells. However, this strategy alleviates the need for hazardous pre-conditioning treatments and will become a viable alternative with further development of modified viral envelopes (Zhang X & Roth, 2010) that target vectors specifically to hematopoietic stem and progenitor cells while minimizing off-target events.

## **7. Safety: Vector genotoxicity, transposon vectors and other issues**

The genotoxicity issue is currently the most immediate and direct safety concern related to the gene therapy using HSCs. Several otherwise successful gene therapy trials of severe combined immunodeficiency using retroviral vectors have resulted in occurrence of leukemia in a significant percentage of patients. Substantial efforts were thus devoted to elucidation of integration patterns and clonal population structure in the hematopoietic compartment after viral transduction, both in experimental models and in clinical trials. The obtained results, although not unanimous, demonstrate nevertheless a frequent occurrence of oligoclonal hematopoiesis after gene therapy, with viral integration sites tending to concentrate in the vicinity of a limited number of genes preferentially involved in growth and proliferation control such as above mentioned *Evi-1*, *PRDM16* or *HMGA2*. Although upregulation of these genes rarely led to overt neoplastic transformation, it is nevertheless clear that the patients with oligoclonal hematopoiesis are at substantial risk of acquiring leukemias at some future time point.

Various strategies are being currently developed to minimize the risk of neoplastic transformations of HSCs after viral transduction. The most promising approaches include using lentiviral instead of retroviral vectors, and insulators to shield cellular oncogenes from activation by strong viral promoters (Puthenveetil et al., 2004). Insulators, however, tends to significantly reduce viral titers (Nielsen et al., 2009), relatively inefficient (Uchida et al., 2011) and do not provide guarantee against insertional activation of potential oncogenes such as *HMGA2* (Cavazzana-Calvo et al., 2010). Another approach is to use promoters specific for differentiated cells that are expected to produce negligible activation of oncogenes in stem cells. However, such promoters tend to provide comparably lower expression levels, and although this might be improved by addition of strong enhancers (Gruh et al., 2008), it is far from certain that such combinations would not activate nearby cellular promoters.

Transposon vectors offer an exciting alternative to retro- and lentiviral vectors. The transposon-based gene delivery combines advantages of integrating viral vectors with those of plasmid vectors. Permanent genomic integration of transposon vectors provides long-term expression, whereas there are significantly fewer constraints on vector design and use

of various function elements like insulators. Transposon systems are inherently less immunogenic than viral delivery systems, whereas their cargo capacity generally exceeds that of retro- and lentiviral vectors (Zayed *et al.*, 2004). Initial experiments with transposons were plagued by low efficiency of integration, but continuous improvements in molecular design of transposases have significantly increased the efficiency of integration process (Mátés *et al.*, 2009). Currently, transposons based on Sleeping Beauty (SB) system represent the most advanced version of this technology (reviewed by Ivics & Izsvák, 2011), although other system such as piggyBac are also being perfected (Yusa *et al.*, 2011) and may offer some advantages, such as larger cargo capacity, over the SB system (Lacoste *et al.*, 2009).

Although stable SB transposon-mediated gene transfer into hematopoietic cells was reported (Xue *et al.*, 2009), efficient vector delivery to HSCs remains poorly resolved issue, which is currently being addressed by using electroporation or hybrid lentiviral-transposon vectors (Staunstrup *et al.*, 2009). Although certain undesired effects such as SB transposase cytotoxicity were observed, it seems that they might be minimized by controllable mRNA delivery (Galla *et al.*, 2011). Compared to lenti- and retroviral vectors that show preferential integration near active genes, SB transposon vectors demonstrate nearly random integration profiles (Moldt *et al.*, 2011), although this property might not be shared by other transposon systems (Huang *et al.*, 2010).

Another serious safety concern is a direct consequence of a current low efficiency of transduction of LTR HSCs, which necessitates the use of myeloablative pre-conditioning and negative selection strategies to eliminate competing endogenous HSCs and increase chimerism levels. Negative selection strategies using in particular alkylating drugs place a significant stress upon hematopoietic system. However, as demonstrated by Xie *et al.*, 2010, repetitive hematopoietic stress by busulfan administration in a nonhuman primate may rapidly lead to reduction of polyclonality and eventually to cytopenia. In addition, potential long term mutagenic effects of alkylating agents are largely unknown, thus adding more uncertainty as to correct assessment of risks and benefits of this strategy. Apparently, in order to tackle efficiently the problem of low transduction efficiency, it is not sufficient to rely on the use of negative selection only, but is also important to achieve substantial improvements in *ex vivo* stem cell culturing, expansion and transduction efficiency. Promising approaches also involve use of positive *ex vivo* and *in vivo* selection and *in situ* transduction strategies.

## 8. Novel technologies

In the recent few years, a group of new exciting and very powerful technologies, namely cell reprogramming using specific combinations of transcription factors and/or micro RNAs appeared (Takahashi & Yamanaka, 2006; Miyoshi *et al.*, 2011). Much hope is invested into development of strategies aiming at derivation of patient-specific induced pluripotent (iPS) cells similar to embryonic stem (ES) cells, with their subsequent differentiation into hematopoietic cells capable of long-term hematopoiesis. In addition to this indirect reprogramming strategy, methods for direct reprogramming that bypass derivation of iPS cells are also being elaborated. There is one report stating that ectopic expression of Oct4 transcription factor in human fibroblasts is sufficient to convert them into hematopoietic cells with *in vivo* engraftment capacity (Szabo *et al.*, 2010). However, whether the published



technique may result in production of bona fide hematopoietic stem cells capable of long-term reconstitution, remains to be seen. It should be noted that such a goal has not yet been achieved for ES or iPS cells. If efficient reprogramming into HSCs were possible, the perspectives would look staggering. First of all, since starting primary cell populations such as mesenchymal stem/progenitor cells can be propagated for many generations and are amenable for selection of efficient vector integration events, it will be possible to obtain cell populations in which the majority of reprogrammed HCS-like cells bear functioning transgenes, thus increasing efficiency of gene therapy many-fold. Besides, if this technology were able to generate ex vivo significantly more reprogrammed cells with HSC properties than is possible to obtain from a patient, this would establish basis for a radical increase in a level of chimerism after transplantation, thus further improving the efficiency of gene therapy. Of course, the safety issues, in particular potential epigenetic and genome instability of reprogrammed cells that might result in neoplastic transformations, must be addressed especially carefully in this case.

## 9. Conclusion

Current protocols of gene therapy of hematopoietic and immune system, despite significant efforts by numerous teams worldwide, demonstrate as yet a relatively modest clinical efficiency. However, there are sufficient reasons to assume that many rather inconspicuous yet significant recent technical developments are preparing the field for a decisive breakthrough in the near future. In addition, new cutting-edge technologies such as direct cell reprogramming are entering the scene and may eventually present a radically different and a more efficient solution of the problem. Given all these considerations, the future of gene therapy of blood and immune system diseases looks definitely bright.

## 10. Acknowledgment

This work was supported by the Russian Foundation for Basic Research Grants 09-04-01312 to F.R. and 11-04-01814-a to A.B, and a grant of the RAS Program of Molecular Cellular Biology to A.B.

## 11. References

- Aguila, J.R.; Liao, W. ; Yang, J., Avila, C.; Hagag, N.; Senzel, L. & Ma, Y. (2011). SALL4 is a robust stimulator for the expansion of hematopoietic stem cells. *Blood*, Vol.118, No.3, (July 2011), pp. 576-585, ISSN 0006-4971
- Antonchuk, J.; Sauvageau, G. & Humphries, R.K. (2002). HOXB4-induced expansion of adult hematopoietic stem cells ex vivo. *Cell*, Vol.109, No.1, (April 2002), pp. 39-45, ISSN 0092-8674
- Beard, B.C.; Trobridge, G.D.; Ironside, C.; McCune, J.S.; Adair, J.E. & Kiem, H.P. (2010). Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates. *The Journal of Clinical Investigation*, Vol.120, No.7, (July 2010), pp. 2345-2354, ISSN 0021-9738
- Bersenev, A.; Wu, C.; Balcerek, J. & Tong, W. (2008). Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2. *The Journal of Clinical Investigation*, Vol.118, No.8, (August 2008), pp. 2832-2844, ISSN 0021-9738



- Bhardwaj, G.; Murdoch, B.; Wu, D.; Baker, D.P.; Williams, K.P.; Chadwick, K.; Ling, L.E.; Karanu, F.N. & Bhatia, M. (2001). Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation. *Nature Immunology*, Vol.2, No.2, (February 2001), pp. 172-180, ISSN 1529-2908
- Bielas, H.; Schmitt, M.; Icreverzi, A.; Ericson, N. & Loeb, L. (2009). Molecularly evolved thymidylate synthase inhibits 5-fluorodeoxyuridine toxicity in human hematopoietic cells. *Human Gene Therapy*, Vol.20, No.12, (December 2009), pp. 703-707, ISSN 1043-0342
- Bowman, J.E.; Reese, J.S.; Lingas, K.T. & Gerson, S.L. (2003). Myeloablation is not required to select and maintain expression of the drug-resistance gene, mutant MGMT, in primary and secondary recipients. *Molecular Therapy*, Vol. 8, No.1, (July 2003), pp. 42-50, ISSN 1525-0016
- Buckley, S.M.; Ulloa-Montoya, F.; Abts, D.; Oostendorp, R.A.; Dzierzak, E.; Ekker, S.C. & Verfaillie, C.M. (2011). Maintenance of HSC by Wnt5a secreting AGM-derived stromal cell line. *Experimental Hematology*, (January 2011), Vol.39, No.1, pp. 114-123.e1-5, ISSN 0301-472X
- Bunting, K.D.; Galipeau, J.; Topham, D.; Benaim, E. & Sorrentino, B.P. (1999). Effects of retroviral-mediated MDR1 expression on hematopoietic stem cell self-renewal and differentiation in culture. *Annals of the New York Academy of Sciences*, Vol.872, (April 1999), pp. 125-141, ISSN 0077-8923
- Case, S.S.; Price, M.A.; Jordan, C.T.; Yu, X.J.; Wang, L.; Bauer, G.; Haas, D.L.; Xu, D.; Stripecke, R.; Naldini, L.; Kohn, D.B. & Crooks, G.M. (1999). Stable transduction of quiescent CD34+CD38- human hematopoietic cells by HIV-1-based lentiviral vectors. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.96, No.6, (March 1999), pp. 2988-2993, ISSN 0027-8424
- Cavazzana-Calvo, M.; Hacein-Bey, S.; de Saint Basile, G.; Gross, F.; Yvon, E.; Nusbaum, P.; Selz, F.; Hue, C.; Certain, S.; Casanova, J.L.; Bousso, P.; Deist, F.L. & Fischer, A. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. *Science*, Vol.288, No.5466, (April 2000), pp. 669-672, ISSN 0036-8075
- Cavazzana-Calvo, M.; Payen, E.; Negre, O.; Wang, G.; Hehir, K.; Fusil, F.; Down, J.; Denaro, M.; Brady, T.; Westerman, K.; Cavallese, R.; Gillet-Legrand, B.; Caccavelli, L.; Sgarra, R.; Maouche-Chrétien, L.; Bernaudin, F.; Giroto, R.; Dorazio, R.; Mulder, G.J.; Polack, A.; Bank, A.; Soulier, J.; Larghero, J.; Kabbara, N.; Dalle, B.; Gourmel, B.; Socie, G.; Chrétien, S.; Cartier, N.; Aubourg, P.; Fischer, A.; Cornetta, K.; Galacteros, F.; Beuzard, Y.; Gluckman, E.; Bushman, F.; Hacein-Bey-Abina, S. & Leboulch, P. (2010). Transfusion independence and HMGA2 activation after gene therapy of human  $\beta$ -thalassaemia. *Nature*, Vol. 467, No.7313, (September 2010), pp. 318-322, ISSN 0028-0836
- Chen, J.; Larochelle, A.; Fricker, S.; Bridger, G.; Dunbar, C.E. & Abkowitz J.L. (2006). Mobilization as a preparative regimen for hematopoietic stem cell transplantation. *Blood*, Vol.107, No.9, (May 2006), pp. 3764-3771, ISSN 0006-4971
- Cheshier, S.H.; Morrison, S.J.; Liao, X. & Weissman, I.L. (1999). In vivo proliferation and cell cycle kinetics of long-term self-renewing haematopoietic stem cells. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.96, No.6, (March 1999), pp. 3120-3125, ISSN 0027-8424

- Chinnasamy, D.; Milsom, M.D.; Shaffer, J.; Neuenfeldt, J.; Shaaban, A.F.; Margison, G.P.; Fairbairn, L.J. & Chinnasamy, N. (2006). Multicistronic lentiviral vectors containing the FMDV 2A cleavage factor demonstrate robust expression of encoded genes at limiting MOI. *Virology Journal*, Vol.3, (March 2006), pp. 14, ISSN 1743-422X
- Chou, S. & Lodish, H.F. (2010). Fetal liver hepatic progenitors are supportive stromal cells for hematopoietic stem cells. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.107, No.17, (April 2010), pp. 7799-7804, ISSN 0027-8424
- Cobas, M.; Wilson, A.; Ernst, B.; Mancini, S.J.; MacDonald, H.R.; Kemler, R. & Radtke, F. (2004). Beta-catenin is dispensable for hematopoiesis and lymphopoiesis. *The Journal of Experimental Medicine*, Vol.199, No.2, (January 2004), pp. 221-229, ISSN 0022-1007
- Cowan, K.H.; Moscow, J.A.; Huang, H.; Zujewski, J.A.; O'Shaughnessy, J.; Sorrentino, B.; Hines, K.; Carter, C.; Schneider, E.; Cusack, G.; Noone, M.; Dunbar, C.; Steinberg, S.; Wilson, W.; Goldspiel, B.; Read, E.J.; Leitman, S.F.; McDonagh, K.; Chow, C.; Abati, A.; Chiang, Y.; Chang, Y.N.; Gottesman, M.M.; Pastan, I. & Nienhuis, A. (1999). Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients. *Clinical Cancer Research*, Vol.5, No.7, (July 1999), pp. 1619-1628, ISSN 1078-0432
- Crcareva, A.; Saito, T.; Kunisato, A.; Kumano, K.; Suzuki, T.; Sakata-Yanagimoto, M.; Kawazu, M.; Stojanovic, A.; Kurokawa, M.; Ogawa, S.; Hirai, H. & Chiba, S. (2005). Hematopoietic stem cells expanded by fibroblast growth factor-1 are excellent targets for retrovirus-mediated gene delivery. *Experimental Hematology*, Vol.33, No.12, (December 2005), pp. 1459-1469, ISSN 0301-472X
- Czechowicz, A.; Kraft, D.; Weissman, I.L. & Bhattacharya, D. (2007). Efficient transplantation via antibody-based clearance of hematopoietic stem cell niches. *Science*, Vol.318, No. 5854, (November 2007), pp. 1296-1299, ISSN 0036-8075
- Davis, B.M.; Koç, O.N. & Gerson, S.L. (2000). Limiting number of G156A O6-methylguanine DNA methyltransferase-transduced marrow progenitors repopulate nonmyeloablated mice after drug selection. *Blood*, Vol. 95, No.10, (May 2000) pp. 3078-3084, ISSN 0006-4971
- de Barros, A.P.; Takiya, C.M.; Garzoni, L.R.; Leal-Ferreira, M.L.; Dutra, H.S.; Chiarini, L.B.; Meirelles, M.N.; Borojevic, R. & Rossi, M.I. (2010). Osteoblasts and bone marrow mesenchymal stromal cells control hematopoietic stem cell migration and proliferation in 3D in vitro model. *PLoS One*, Vol.5, No.2, (February 2010), pp. e9093, ISSN 1932-6203
- de Haan, G.; Weersing, E.; Dontje, B.; van Os, R.; Bystrykh, L.V.; Vellenga, E. & Miller, G. (2003). In vitro generation of long-term repopulating hematopoietic stem cells by fibroblast growth factor-1. *Developmental Cell*, Vol.4, No.2, (February 2003), pp. 241-251, ISSN 1534-5807
- Delaney, C.; Heimfeld, S.; Brashem-Stein, C.; Voorhies, H.; Manger, R.L. & Bernstein, I.D. (2010). Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. *Nature Medicine*, Vol.16, No.2, (February 2010), pp. 232-236, ISSN 1078-8956

- De Toni, F.; Poglio, S.; Youcef, A.B.; Cousin, B.; Pflumio, F.; Bourin, P.; Casteilla, L. & Laharrague, P. (2011). Human Adipose-Derived Stromal Cells Efficiently Support Hematopoiesis In Vitro and In Vivo: A Key Step for Therapeutic Studies. *Stem Cells and Development*, (April 2011), advance online publication, ISSN 1547-3287
- Domashenko, A.D.; Danet-Desnoyers, G.; Aron, A.; Carroll, M.P. & Emerson, S.G. (2010). TAT-mediated transduction of NF- $\kappa$ B peptide induces the ex vivo proliferation and engraftment potential of human hematopoietic progenitor cells. *Blood*, Vol.116, No.15, (October 2010), pp. 2676-2683, ISSN 0006-4971
- Du, Y.; Jenkins, N.A. & Copeland, N.G. (2005). Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. *Blood*, Vol.106, No.12, (December 2005), pp. 3932-3939, ISSN 0006-4971
- Ellis, J. (2005). Silencing and variegation of gammaretrovirus and lentivirus vectors. *Human Gene Therapy*, Vol.16, No.11, (November 2005), pp. 1241-1246, ISSN 1043-0342
- Frisch, B.J.; Porter, R.L.; Gigliotti, B.J.; Olm-Shipman, A.J.; Weber, J.M.; O'Keefe, R.J.; Jordan, C.T. & Calvi, L.M. (2009). In vivo prostaglandin E2 treatment alters the bone marrow microenvironment and preferentially expands short-term hematopoietic stem cells. *Blood*, Vol.114, No.19, (November 2009), pp. 4054-4063, ISSN 0006-4971
- Galla, M.; Schambach, A.; Falk, C.S.; Maetzig, T.; Kuehle, J.; Lange, K.; Zychlinski, D.; Heinz, N.; Brugman, M.H.; Göhring, G.; Izsvák, Z.; Ivics, Z. & Baum, C. (2011). Avoiding cytotoxicity of transposases by dose-controlled mRNA delivery. *Nucleic Acids Research*, Vol.39, No.16, (September 2011), pp. 7147-7160, ISSN 0305-1048
- Goldman, D.C.; Bailey, A.S.; Pfaffle, D.L.; Al Masri, A.; Christian, J.L. & Fleming, W.H. (2009). BMP4 regulates the hematopoietic stem cell niche. *Blood*, Vol.114, No.20, (November 2009), pp. 4393-4401, ISSN 0006-4971
- Gori, J.L.; McIvor, R. & Kaufman, D. (2010). Methotrexate supports in vivo selection of human embryonic stem cell derived-hematopoietic cells expressing dihydrofolate reductase. *Bioengineered Bugs*, Vol.1, No.6, (November 2010), pp. 434-436, ISSN 1949-1018
- Guo, S.; Lu, J.; Schlanger, R.; Zhang, H.; Wang, J.Y.; Fox, M.C.; Purton, L.E.; Fleming, H.H.; Cobb, B.; Merckenschlager, M.; Golub, T.R. & Scadden, D.T. (2010). MicroRNA miR-125a controls hematopoietic stem cell number. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.107, No.32, (August 2010), pp. 14229-14234, ISSN 0027-8424
- Gruh, I.; Wunderlich, S.; Winkler, M.; Schwanke, K.; Heinke, J.; Blömer, U.; Ruhparwar, A.; Rohde, B.; Li, R.K.; Haverich, A. & Martin, U. (2008). Human CMV immediate-early enhancer: a useful tool to enhance cell-type-specific expression from lentiviral vectors. *The Journal of Gene Medicine*, Vol.10, No.1, (January 2008), pp. 21-32, ISSN 1099-498X
- Heath, V.; Suh, H.C.; Holman, M.; Renn, K.; Gooya, J.M.; Parkin, S.; Klarmann, K.D.; Ortiz, M.; Johnson, P. & Keller, J. (2004). C/EBP $\alpha$  deficiency results in hyperproliferation of hematopoietic progenitor cells and disrupts macrophage development in vitro and in vivo. *Blood*, Vol.104, No.6, (September 2004), pp. 1639-1647, ISSN 0006-4971
- Hofmann, I.; Stover, E.H.; Cullen, D.E.; Mao, J.; Morgan, K.J.; Lee, B.H.; Kharas, M.G.; Miller, P.G.; Cornejo, M.G.; Okabe, R.; Armstrong, S.A.; Ghilardi, N.; Gould, S.; de Sauvage, F.J.; McMahon, A.P. & Gilliland, D.G. (2009). Hedgehog signaling is

- dispensable for adult murine hematopoietic stem cell function and hematopoiesis. *Cell Stem Cell*, Vol.4, No.6, (June 2009), pp. 559-567, ISSN 1934-5909
- Horn, P.A.; Morris, J.C.; Bukovsky, A.A.; Andrews, R.G.; Naldini, L.; Kurre, P. & Kiem, H.P. (2002). Lentivirus-mediated gene transfer into hematopoietic repopulating cells in baboons. *Gene Therapy*, Vol.9, No.21, (November 2002), pp. 1464-1471, ISSN 0969-7128
- Hosokawa, K.; Arai, F.; Yoshihara, H.; Iwasaki, H.; Nakamura, Y.; Gomei, Y. & Suda, T. (2010). Knockdown of N-cadherin suppresses the long-term engraftment of hematopoietic stem cells. *Blood*, Vol.116, No.4, (July 2010), pp. 554-563, ISSN 0006-4971
- Huang, X.; Guo, H.; Tammana, S.; Jung, Y.C.; Mellgren, E.; Bassi, P.; Cao, Q.; Tu, Z.J.; Kim, Y.C.; Ekker, S.C.; Wu, X.; Wang, S.M. & Zhou, X. (2010). Gene transfer efficiency and genome-wide integration profiling of Sleeping Beauty, Tol2, and piggyBac transposons in human primary T cells. *Molecular Therapy*, Vol.18, No.10, (October 2010), pp. 1803-1813, ISSN 1525-0016
- Hutton, J.F.; Rozenkov, V.; Khor, F.S.; D'Andrea, R.J. & Lewis, I.D. (2006). Bone morphogenetic protein 4 contributes to the maintenance of primitive cord blood hematopoietic progenitors in an ex vivo stroma-noncontact co-culture system. *Stem Cells and Development*, Vol.15, No.6, (December 2006), pp. 805-813, ISSN 1547-3287
- Huynh, H.; Iizuka, S.; Kaba, M.; Kirak, O.; Zheng, J.; Lodish, H.F. & Zhang, C.C. (2008). Insulin-like growth factor-binding protein 2 secreted by a tumorigenic cell line supports ex vivo expansion of mouse hematopoietic stem cells. *Stem Cells*, Vol.26, No.6, (June 2008), pp. 1628-1635, ISSN 1066-5099
- Ikeda, K.; Mason, P.J. & Bessler M. (2011). 3'UTR-truncated Hmga2 cDNA causes MPN-like hematopoiesis by conferring a clonal growth advantage at the level of HSC in mice. *Blood*, Vol.117, No.22, (June 2011), pp. 5860-5869, ISSN 0006-4971
- Imai, Y.; Adachi, Y.; Shi, M.; Shima, C.; Yanai, S.; Okigaki, M.; Yamashima, T.; Kaneko, K. & Ikehara, S. (2010). Caspase inhibitor ZVAD-fmk facilitates engraftment of donor hematopoietic stem cells in intra-bone marrow-bone marrow transplantation. *Stem Cells and Development*, Vol.19, No.4, (April 2010), pp. 461-468, ISSN 1547-3287
- Ivics, Z. & Izsvák, Z. (2011). Non-viral Gene Delivery with the Sleeping Beauty Transposon System. *Human Gene Therapy*, (August 2011), advance online publication, ISSN 1043-0342
- Iwama, A.; Oguro, H.; Negishi, M.; Kato, Y.; Morita, Y.; Tsukui, H.; Ema, H.; Kamijo, T.; Katoh-Fukui, Y.; Koseki, H.; van Lohuizen, M. & Nakauchi, H. (2004). Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. *Immunity*, Vol.21, No.6, (December 2004), pp. 843-851, ISSN 1074-7613
- Khoury, M.; Drake, A.; Chen, Q.; Dong, D.; Leskov, I.; Fragoso, M.F.; Li, Y.; Iliopoulou, B.P.; Hwang, W.; Lodish, H.F. & Chen, J. (2011). Mesenchymal stem cells secreting angiopoietin-like-5 support efficient expansion of human hematopoietic stem cells without compromising their repopulating potential. *Stem Cells and Development*, Vol.20, No.8, (August 2011), pp. 1371-1381, ISSN 1547-3287
- Kiel, M.J.; Radice, G.L. & Morrison, S.J. (2007). Lack of evidence that hematopoietic stem cells depend on N-cadherin-mediated adhesion to osteoblasts for their maintenance. *Cell Stem Cell*, Vol.1, No.2, (August 2007), pp. 204-217, ISSN 1934-5909



- King, K.Y.; Baldridge, M.T.; Weksberg, D.C.; Chambers, S.M.; Lukov, G.L.; Wu, S.; Boles, N.C.; Jung, S.Y.; Qin, J.; Liu, D.; Songyang, Z.; Eissa, N.T.; Taylor, G.A. & Goodell, M.A. (2011). Irgm1 protects hematopoietic stem cells by negative regulation of IFN signaling. *Blood*, Vol.118, No. 6, (August 2011), pp. 1525-33, ISSN 0006-4971
- Ko, K.H.; Holmes, T.; Palladinetti, P.; Song, E.; Nordon, R.; O'Brien, T.A. & Dolnikov, A. (2011). GSK-3 $\beta$  inhibition promotes engraftment of ex vivo-expanded hematopoietic stem cells and modulates gene expression. *Stem Cells*, Vol.29, No.1, (January 2011), pp. 108-118, ISSN 1066-5099
- Kobune, M.; Ito, Y.; Kawano, Y.; Sasaki, K.; Uchida, H.; Nakamura, K.; Dehari, H.; Chiba, H.; Takimoto, R.; Matsunaga, T.; Terui, T.; Kato, J.; Niitsu, Y. & Hamada, H. (2004). Indian hedgehog gene transfer augments hematopoietic support of human stromal cells including NOD/SCID-beta2m<sup>-/-</sup> repopulating cells. *Blood*, Vol.104, No.4, (August 2004), pp. 1002-1009, ISSN: 0006-4971
- Konuma, T.; Nakamura, S.; Miyagi, S.; Negishi, M.; Chiba, T.; Oguro, H.; Yuan, J.; Mochizuki-Kashio, M.; Ichikawa, H.; Miyoshi, H.; Vidal, M. & Iwama, A. (2011). Forced expression of the histone demethylase Fbxl10 maintains self-renewing hematopoietic stem cells. *Experimental Hematology*, Vol.39, No.6, (June 2011), pp. 697-709.e5, ISSN 0301-472X
- Krosl, J.; Austin, P.; Beslu, N.; Kroon, E.; Humphries, R.K. & Sauvageau, G. (2003). In vitro expansion of hematopoietic stem cells by recombinant TAT-HOXB4 protein. *Nature Medicine*, Vol.9, No.11, (November 2003), pp. 1428-1432, ISSN 1078-8956
- Lacoste, A.; Berenshteyn, F. & Brivanlou, A.H. (2009). An efficient and reversible transposable system for gene delivery and lineage-specific differentiation in human embryonic stem cells. *Cell Stem Cell*, Vol.5, No.3, (September 2009), pp. 332-342, ISSN 1934-5909
- Larochelle, A.; Choi, U.; Shou, Y.; Naumann, N.; Loktionova, N.A.; Clevenger, J.R.; Krouse, A.; Metzger, M.; Donahue, R.E.; Kang, E.; Stewart, C.; Persons, D.; Malech, H.L.; Dunbar, C.E. & Sorrentino, B.P. (2009). In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene. *The Journal of Clinical Investigation*, Vol.119, No.7, (July 2009), pp. 1952-1963, ISSN 0021-9738
- Lutolf, M.P.; Doyonnas, R.; Havenstrite, K.; Kolekar, K. & Blau, H.M. (2009). Perturbation of single hematopoietic stem cell fates in artificial niches. *Integrative biology*, Vol.1, No.1, (January 2009), pp. 59-69, ISSN 1757-9694
- Masuda, S.; Ageyama, N.; Shibata, H.; Obara, Y.; Ikeda, T.; Takeuchi, K.; Ueda, Y.; Ozawa, K. & Hanazono, Y. (2009). Cotransplantation with MSCs improves engraftment of HSCs after autologous intra-bone marrow transplantation in nonhuman primates. *Experimental Hematology*, Vol.37, No.10, (October 2009), pp. 1250-1257.e1, ISSN 0301-472X
- Mátés, L.; Chuah, M.K.; Belay, E.; Jerchow, B.; Manoj, N.; Acosta-Sanchez, A.; Grzela, D.P.; Schmitt, A.; Becker, K.; Matrai, J.; Ma, L.; Samara-Kuko, E.; Gysemans, C.; Pryputniewicz, D.; Miskey, C.; Fletcher, B.; VandenDriessche, T.; Ivics, Z. & Izsvák, Z. (2009). Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. *Nature Genetics*, Vol.41, No.6, (June 2009), pp. 753-761, ISSN 1061-4036



- Mazurier, F.; Doedens, M.; Gan, O.I. & Dick, J.E. (2003). Rapid myeloerythroid repopulation after intrafemoral transplantation of NOD-SCID mice reveals a new class of human stem cells. *Nature Medicine*, Vol.9, No.7, (July 2003), pp. 959-963, ISSN 1078-8956
- McCauslin, C.S.; Wine, J.; Cheng, L.; Klarmann, K.D.; Candotti, F.; Clausen, P.A.; Spence, S.E. & Keller, J.R. (2003). In vivo retroviral gene transfer by direct intrafemoral injection results in correction of the SCID phenotype in Jak3 knock-out animals. *Blood*, Vol.102, No.3, (August 2003), pp. 843-848, ISSN 0006-4971
- McCormack, M.P.; Forster, A.; Drynan, L.; Pannell, R. & Rabbitts, T.H. (2003). The LMO2 T-cell oncogene is activated via chromosomal translocations or retroviral insertion during gene therapy but has no mandatory role in normal T-cell development. *Molecular and Cellular Biology*, Vol.23, No.24, (December 2003), pp. 9003-9013, ISSN 0270-7306
- McCormack, M.P.; Young, L.F.; Vasudevan, S.; de Graaf, C.A.; Codrington, R.; Rabbitts, T.H.; Jane, S.M. & Curtis, D.J. (2010). The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal. *Science*, Vol.327, No.5967, (February 2010), pp. 879-883, ISSN 0036-8075
- Métais, J.Y. & Dunbar, C.E. (2008). The MDS1-EVI1 gene complex as a retrovirus integration site: impact on behavior of hematopoietic cells and implications for gene therapy. *Molecular Therapy*, Vol.16, No.3, (March 2008), pp. 439-449, ISSN 1525-0016
- Milsons M.D.; Woolford L.B.; Margison G.P.; Humphries R.K. & Fairbairn L.J. (2004). Enhanced in vivo selection of bone marrow cells by retroviral-mediated coexpression of mutant O6-methylguanine-DNA-methyltransferase and HOXB4. *Molecular Therapy*, Vol.10, No.5, (November 2004), pp. 862-873, ISSN 1525-0016
- Miyoshi, H.; Muraio, M.; Ohshima, N. & Tun T. (2011). Three-dimensional culture of mouse bone marrow cells within a porous polymer scaffold: effects of oxygen concentration and stromal layer on expansion of haematopoietic progenitor cells. *Journal of Tissue Engineering and Regenerative Medicine*, Vol.5, No.2, (February 2011), pp. 112-118, ISSN 1932-6254
- Miyoshi, N.; Ishii, H.; Nagano, H.; Haraguchi, N.; Dewi, D.L.; Kano, Y.; Nishikawa, S.; Tanemura, M.; Mimori, K.; Tanaka, F.; Saito, T.; Nishimura, J.; Takemasa, I.; Mizushima, T.; Ikeda, M.; Yamamoto, H.; Sekimoto, M.; Doki, Y. & Mori, M. (2011). Reprogramming of mouse and human cells to pluripotency using mature microRNAs. *Cell Stem Cell*, Vol.8, No.6, (June 2011), pp. 633-638, ISSN 1934-5909
- Moldenhauer, A.; Futschik, M.; Lu, H.; Helmig, M.; Götze, P.; Bal, G.; Zenke, M.; Han, W. & Salama, A. (2011). Interleukin 32 promotes hematopoietic progenitor expansion and attenuates bone marrow cytotoxicity. *European Journal of Immunology*, Vol.41, No.6, (June 2011), pp. 1774-1786, ISSN: 0014-2980
- Moldt, B.; Miskey, C.; Staunstrup, N.H.; Gogol-Döring, A.; Bak, R.O.; Sharma, N.; Mátés, L.; Izsvák, Z.; Chen, W.; Ivics, Z. & Mikkelsen, J.G. (2011). Comparative Genomic Integration Profiling of Sleeping Beauty Transposons Mobilized With High Efficacy From Integrase-defective Lentiviral Vectors in Primary Human Cells. *Molecular Therapy*, Vol.19, No.8, (August 2011), pp. 1499-1510, ISSN 1043-0342
- Moore, K.A.; Ema, H. & Lemischka, I.R. (1997). In vitro maintenance of highly purified, transplantable hematopoietic stem cells. *Blood*, Vol.89, No.12, pp. 4337-4347, ISSN 0006-4971

- Mori, M.; Yoneda-Kato, N.; Yoshida, A. & Kato, J.Y. (2008). Stable form of JAB1 enhances proliferation and maintenance of hematopoietic progenitors. *Journal of Biological Chemistry*, Vol.283, No.43, (October 2008), pp. 29011-29021, ISSN 0021-9258
- Mostoslavsky, G.; Kotton, D.N.; Fabian, A.J.; Gray, J.T.; Lee, J.S. & Mulligan, R.C. (2005). Efficiency of transduction of highly purified murine hematopoietic stem cells by lentiviral and oncoretroviral vectors under conditions of minimal in vitro manipulation. *Molecular Therapy*, Vol.11, No.6, (June 2005), pp. 932-940, ISSN 1525-0016
- Mullican, S.E.; Zhang, S.; Konopleva, M.; Ruvolo, V.; Andreeff, M.; Milbrandt, J. & Conneely, O.M. (2007). Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia. *Nature Medicine*, Vol.13, No.6, (June 2007), pp. 730-735, ISSN 1078-8956
- Neff, T.; Beard, B.C.; Peterson, L.J.; Anandakumar, P.; Thompson, J. & Kiem, H.P. (2005). Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy. *Blood*, Vol.105, No.3, (February 2005), pp. 997-1002, ISSN 0006-4971
- Nemeth, M.J.; Topol, L.; Anderson, S.M.; Yang, Y. & Bodine, D.M. (2007). Wnt5a inhibits canonical Wnt signaling in hematopoietic stem cells and enhances repopulation. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.104, No.39, (September 2007), pp. 15436-15441, ISSN 0027-8424
- Nemeth, M.J.; Mak, K.K.; Yang, Y. & Bodine, D.M. (2009). beta-Catenin expression in the bone marrow microenvironment is required for long-term maintenance of primitive hematopoietic cells. *Stem Cells*, Vol.27, No.5, (May 2009), pp. 1109-1119, ISSN 1066-5099
- Nielsen, T.T.; Jakobsson, J.; Rosenqvist, N. & Lundberg, C. (2009). Incorporating double copies of a chromatin insulator into lentiviral vectors results in less viral integrants. *BMC Biotechnology*, Vol.9, (February 2009), pp. 9-13, ISSN 1472-6750
- North, T.E.; Goessling, W.; Walkley, C.R.; Lengerke, C.; Kopani, K.R.; Lord, A.M.; Weber, G.J.; Bowman, T.V.; Jang, I.H.; Grosser, T.; Fitzgerald, G.A.; Daley, G.Q.; Orkin, S.H. & Zon, L.I. (2007). Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. *Nature*, Vol.447, No.7147, (June 2007), pp. 1007-1011, ISSN 0028-0836
- Ohta, H.; Sekulovic, S.; Bakovic, S.; Eaves, C.J.; Pineault, N.; Gasparetto, M.; Smith, C.; Sauvageau, G. & Humphries, R.K. (2007). Near-maximal expansions of hematopoietic stem cells in culture using NUP98-HOX fusions. *Experimental Hematology*, Vol.35, No.5, (May 2007), pp. 817-830, ISSN 0301-472X
- Ott, M.G.; Schmidt, M.; Schwarzwaelder, K.; Stein, S.; Siler, U.; Koehl, U.; Glimm, H.; Kühlcke, K.; Schilz, A.; Kunkel, H.; Naundorf, S.; Brinkmann, A.; Deichmann, A.; Fischer, M.; Ball, C.; Pilz, I.; Dunbar, C.; Du, Y.; Jenkins, N.A.; Copeland, N.G.; Lüthi, U.; Hassan, M.; Thrasher, A.J.; Hoelzer, D.; von Kalle, C.; Seger, R. & Grez, M. (2006). Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. *Nature Medicine*, Vol.12, No.4, (April 2006), pp. 401-409, ISSN 1078-8956
- Pan, D. (2009). In situ (in vivo) gene transfer into murine bone marrow stem cells. *Methods in Molecular Biology*, Vol.506, pp. 159-169, ISSN 1064-3745
- Park, I.K.; Qian, D.; Kiel, M.; Becker, M.W.; Pihalja, M.; Weissman, I.L.; Morrison, S.J. & Clarke, M.F. (2003). Bmi-1 is required for maintenance of adult self-renewing

- haematopoietic stem cells. *Nature*, Vol.423, No.6937, (May 2003), pp. 302-305, ISSN 0028-0836
- Peled, T.; Landau, E.; Mandel, J.; Glukhman, E.; Goudsmid, N.R.; Nagler, A. & Fibach, E. (2004). Linear polyamine copper chelator tetraethylenepentamine augments long-term ex vivo expansion of cord blood-derived CD34+ cells and increases their engraftment potential in NOD/SCID mice. *Experimental Hematology*, Vol.32, No.6, (June 2004), pp. 547-555, ISSN 0301-472X
- Persons, D.A.; Allay, E.R.; Sawai, N.; Hargrove, P.W.; Brent, T.P.; Hanawa, H.; Nienhuis, A.W. & Sorrentino, B.P. (2003). Successful treatment of murine beta-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells. *Blood*, Vol.102, No.2, (July 2003), pp. 506-513, ISSN 0006-4971
- Podda, S.; Ward, M.; Himelstein, A.; Richardson, C.; de la Flor-Weiss, E.; Smith, L.; Gottesman, M.; Pastan, I. & Bank, A. (1992). Transfer and expression of the human multiple drug resistance gene into live mice. *Proceedings of the National Academy of Sciences of the United States of America*, Vol. 89, No.20, (October 1992), pp. 9676-9680, ISSN 0027-8424
- Puthenveetil, G.; Scholes, J.; Carbonell, D.; Qureshi, N.; Xia, P.; Zeng, L.; Li, S.; Yu, Y.; Hiti, A.L.; Yee, J.K. & Malik, P. (2004). Successful correction of the human beta thalassemia major phenotype using a lentiviral vector. *Blood*, Vol.104, No.12, (December 2004), pp. 3445-3453, ISSN 0006-4971
- Ragg, S.; Xu-Welliver, M.; Bailey, J.; D'Souza, M.; Cooper, R.; Chandra, S.; Seshadri, R.; Pegg, A.E. & Williams, D.A. (2000). Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. *Cancer Research*, Vol.60, No.18, (September 2000), pp. 5187-5195, ISSN 0008-5472
- Ramirez, P.; Rettig, M.P.; Uy, G.L.; Deych, E.; Holt, M.S.; Ritchey, J.K. & DiPersio, J.F. (2009). BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. *Blood*, Vol.114, No.7, (August 2009), pp. 1340-1343, ISSN 0006-4971
- Reya, T.; Duncan, A.W.; Ailles, L.; Domen, J.; Scherer, D.C.; Willert, K.; Hintz, L.; Nusse, R. & Weissman I.L. (2003). A role for Wnt signalling in self-renewal of haematopoietic stem cells. *Nature*, Vol.423, No.6938, (May 2003), pp. 409-414, ISSN 0028-0836
- Richard, E.; Robert, E.; Cario-André, M.; Ged, C.; Géronimi, F.; Gerson, S.L.; de Verneuil, H. & Moreau-Gaudry, F. (2004). Hematopoietic stem cell gene therapy of murine protoporphyria by methylguanine-DNA methyltransferase-mediated in vivo drug selection. *Gene Therapy*, Vol.11, No.22, (November 2004), pp. 1638-1647, ISSN 0969-7128
- Rizo, A.; Dontje, B.; Vellenga, E.; de Haan, G. & Schuringa, J.J. (2008). Long-term maintenance of human hematopoietic stem/progenitor cells by expression of BMI1. *Blood*, Vol.111, No.5, (March 2008), pp. 2621-2630, ISSN 0006-4971
- Rohrbaugh, S.L.; Campbell, T.B.; Hangoc, G. & Broxmeyer, H.E. (2011). Ex vivo rapamycin treatment of human cord blood CD34(+) cells enhances their engraftment of NSG mice. *Blood Cells, Molecules, & Diseases*, Vol.46, No.4, (April 2011), pp. 318-320, ISSN 1079-9796
- Sangeetha, V.M.; Kale, V.P. & Limaye, LS. (2010). Expansion of cord blood CD34 cells in presence of zVADfmk and zLLYfmk improved their in vitro functionality and in

- vivo engraftment in NOD/SCID mouse. *PLoS One*, Vol.5, No.8, (August 2010), pp. e12221, ISSN 1932-6203
- Sato, T.; Onai, N.; Yoshihara, H.; Arai, F.; Suda, T. & Ohteki, T. (2009). Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion. *Nature Medicine*, Vol.15, No.6, (June 2009), pp. 696-700, ISSN 1078-8956
- Sauvageau, G.; Thorsteinsdottir, U.; Eaves, C.J.; Lawrence, H.J.; Largman, C.; Lansdorp, P.M. & Humphries, R.K. (1995). Overexpression of HOXB4 in hematopoietic cells causes the selective expansion of more primitive populations in vitro and in vivo. *Genes & Development*, Vol.9, No.14, (July 1995), pp. 1753-1765, ISSN. 0890-9369
- Sawai, N.; Zhou, S.; Vanin, E.; Houghton, P.; Brent, T. & Sorrentino, B. (2001). Protection and in Vivo Selection of Hematopoietic Stem Cells Using Temozolomide, O6-Benzylguanine, and an Alkyltransferase-Expressing Retroviral Vector. *Molecular Therapy*, Vol.3, No.1, (January 2001), pp. 78-87, ISSN 1525-0016
- Scheller, M.; Huelsken, J.; Rosenbauer, F.; Taketo, M.M.; Birchmeier, W.; Tenen, D.G. & Leutz, A. (2006). Hematopoietic stem cell and multilineage defects generated by constitutive beta-catenin activation. *Nature Immunology*, Vol.7, No.10, (October 2006), pp. 1037-1047, ISSN 1529-2908
- Schmidt, M.; Carbonaro, D.A.; Speckmann, C.; Wissler, M.; Bohnsack, J.; Elder, M.; Aronow, B.J.; Nolta, J.A.; Kohn, D.B. & von Kalle, C. (2003). Clonality analysis after retroviral-mediated gene transfer to CD34+ cells from the cord blood of ADA-deficient SCID neonates. *Nature Medicine*, Vol.9, No.4, (April 2003), pp. 463-468, ISSN 1078-8956
- Sellers, S.; Gomes, T.J.; Larochelle, A.; Lopez, R.; Adler, R.; Krouse, A.; Donahue, R.E.; Childs, R.W. & Dunbar, C.E. (2010). Ex vivo expansion of retrovirally transduced primate CD34+ cells results in overrepresentation of clones with MDS1/EVI1 insertion sites in the myeloid lineage after transplantation. *Molecular Therapy*, Vol.18, No.9, (September 2010), pp. 1633-1639, ISSN 1525-0016
- Shepherd, B.E.; Kiem, H.P.; Lansdorp, P.M.; Dunbar, C.E.; Aubert, G.; LaRochelle, A.; Seggewiss, R.; Gutter, P. & Abkowitz, J.L. (2007). Hematopoietic stem-cell behavior in nonhuman primates. *Blood*, Vol.110, No.6, (September 2007) pp. 1806-1813, ISSN 0006-4971
- Sorrentino, B.P.; Brandt, S.J.; Bodine, D.; Gottesman, M.; Pastan, I.; Cline, A. & Nienhuis A.W. (1992). Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. *Science*, Vol.257, No.5066, (July 1992), pp. 99-103, ISSN 0036-8075
- Staunstrup, N.H.; Moldt, B.; Mátés, L.; Villesen, P.; Jakobsen, M.; Ivics, Z.; Izsvák, Z. & Mikkelsen, J.G. (2009). Hybrid lentivirus-transposon vectors with a random integration profile in human cells. *Molecular Therapy*, Vol.17, No.7, (July 2009), pp. 1205-1214, ISSN 1525-0016
- Stein, S.; Ott, M.G.; Schultze-Strasser, S.; Jauch, A.; Burwinkel, B.; Kinner, A.; Schmidt, M.; Krämer, A.; Schwäble, J.; Glimm, H.; Koehl, U.; Preiss, C.; Ball, C.; Martin, H.; Göhring, G.; Schwarzwaelder, K.; Hofmann, W.K.; Karakaya, K.; Tchatchou, S.; Yang, R.; Reinecke, P.; Köhlcke, K.; Schlegelberger, B.; Thrasher, A.J.; Hoelzer, D.; Seger, R.; von Kalle, C. & Grez, M. (2010). Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic




- granulomatous disease. *Nature Medicine*, Vol.16, No.2, (February 2010), pp. 198-204, ISSN 1078-8956
- Szabo, E.; Rampalli, S.; Risueño, R.M.; Schnerch, A.; Mitchell, R.; Fiebig-Comyn, A.; Levadoux-Martin, M. & Bhatia, M. (2010). Direct conversion of human fibroblasts to multilineage blood progenitors. *Nature*, Vol.468, No.7323, (November 2010), pp. 521-526, ISSN 0028-0836
- Takahashi, K. & Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell*, Vol.126, No.4, (August 2006), pp. 663-676, ISSN 0092-8674
- Tan, J.; Liu, T.; Hou, L.; Meng, W.; Wang, Y.; Zhi, W. & Deng, L. (2010). Maintenance and expansion of hematopoietic stem/progenitor cells in biomimetic osteoblast niche. *Cytotechnology*, Vol.62, No.5, (October 2010), pp. 439-448, ISSN 0920-9069
- Toda, H.; Yamamoto, M.; Kohara, H. & Tabata, Y. (2011). Orientation-regulated immobilization of Jagged1 on glass substrates for ex vivo proliferation of a bone marrow cell population containing hematopoietic stem cells. *Biomaterials*, Vol.32, No.29, (October 2011), pp. 6920-6928, ISSN 0142-9612
- Trobridge, G. & Russell, D.W. (2004). Cell cycle requirements for transduction by foamy virus vectors compared to those of oncovirus and lentivirus vectors. *Journal of Virology*, Vol.78, No.5, (March 2004), pp. 2327-2335, ISSN 0022-538X
- Trobridge, G.D.; Wu, R.A.; Beard, B.C.; Chiu, S.Y.; Muñoz, N.M.; von Laer, D.; Rossi, J.J. & Kiem, H.P. (2009). Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection. *PLoS ONE*, Vol.4, No.11, (November 2009), pp. e7693, ISSN 1932-6203
- Trowbridge, J.J.; Xenocostas, A.; Moon, R.T. & Bhatia, M. (2006). Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation. *Nature Medicine*, Vol.12, No.1, (January 2006), pp. 89-98, ISSN 1078-8956
- Uchida, N.; Sutton, R.E.; Frieria, A.M.; He, D.; Reitsma, M.J.; Chang, W.C.; Veres, G.; Scollay, R. & Weissman, I.L. (1998). HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated G0/G1 human hematopoietic stem cells. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.95, No.20, (September 1998), pp. 11939-11944, ISSN 0027-8424
- Uchida, N.; Washington, K.N.; Lap, C.J.; Hsieh, M.M. & Tisdale, J.F. (2011). Chicken HS4 insulators have minimal barrier function among progeny of human hematopoietic cells transduced with an HIV1-based lentiviral vector. *Molecular Therapy*, Vol.19, No.1, (January 2011), pp. 133-139, ISSN 1525-0016
- Ueno, H.; Sakita-Ishikawa, M.; Morikawa, Y.; Nakano, T.; Kitamura, T. & Saito, M. (2003). A stromal cell-derived membrane protein that supports hematopoietic stem cells. *Nature Immunology*, Vol.4, No.5, (May 2003), pp. 457-463, ISSN 1529-2908
- VandenDriessche, T.; Ivics, Z.; Izsvák, Z. & Chuah, M.K. (2009). Emerging potential of transposons for gene therapy and generation of induced pluripotent stem cells. *Blood*, Vol.114, No.8, (August 2009), pp. 1461-1468, ISSN 0006-4971
- Varnum-Finney, B.; Xu, L.; Brashem-Stein, C.; Nourigat, C.; Flowers, D.; Bakkour, S.; Pear, W.S. & Bernstein, I.D. (2000). Pluripotent, cytokine-dependent, hematopoietic stem cells are immortalized by constitutive Notch1 signaling. *Nature Medicine*, Vol.6, No.11, (November 2000), pp. 1278-1281, ISSN 1078-8956



- Vercauteren, S.M. & Sutherland, H.J. (2004). Constitutively active Notch4 promotes early human hematopoietic progenitor cell maintenance while inhibiting differentiation and causes lymphoid abnormalities in vivo. *Blood*, Vol.104, No.8, (October 2004), pp. 2315-2322, ISSN: 0006-4971
- Wagner, W.; Roderburg, C.; Wein, F.; Diehlmann, A.; Frankhauser, M.; Schubert, R.; Eckstein, V. & Ho, A.D. (2007). Molecular and secretory profiles of human mesenchymal stromal cells and their abilities to maintain primitive hematopoietic progenitors. *Stem Cells*, Vol.25, No.10, (October 2007), pp. 2638-2647, ISSN 1066-5099
- Wang, G.P.; Berry, C.C.; Malani, N.; Leboulch, P.; Fischer, A.; Hacein-Bey-Abina, S.; Cavazzana-Calvo, M. & Bushman, F.D. (2010). Dynamics of gene-modified progenitor cells analyzed by tracking retroviral integration sites in a human SCID-X1 gene therapy trial. *Blood*, Vol.115, No.22, (June 2010), pp. 4356-4366, ISSN 0006-4971
- Wang, X.; Hisha, H.; Taketani, S.; Inaba, M.; Li, Q.; Cui, W.; Song, C.; Fan, T.; Cui, Y.; Guo, K.; Yang, G.; Fan, H.; Lian, Z.; Gershwin, M.E. & Ikehara, S. (2005). Neural cell adhesion molecule contributes to hemopoiesis-supporting capacity of stromal cell lines. *Stem Cells*, Vol.23, No.9, (October 2005), pp. 1389-1399, ISSN 1066-5099
- Wang, Y.; Kellner, J.; Liu, L. & Zhou, D. (2011). Inhibition of p38 Mitogen-Activated Protein Kinase Promotes Ex Vivo Hematopoietic Stem Cell Expansion. *Stem Cells and Development*, Vol.20, No.7, (July 2011), pp. 1143-1152, ISSN 1547-3287
- Watts, K.L.; Zhang, X.; Beard, B.C.; Chiu, S.Y.; Trobridge, G.D.; Humphries, R.K. & Kiem, H.P. (2011). Differential Effects of HOXB4 and NUP98-HOXA10hd on Hematopoietic Repopulating Cells in a Nonhuman Primate Model. *Human Gene Therapy*, (September 2011), advance online publication, ISSN 1525-0016
- Willert, K.; Brown, J.D.; Danenberg, E.; Duncan, A.W.; Weissman, I.L.; Reya, T.; Yates, J.R. 3rd & Nusse, R. (2003). Wnt proteins are lipid-modified and can act as stem cell growth factors. *Nature*, Vol.423, No.6938, (May 2003), pp. 448-452, ISSN 0028-0836
- Xie, J.; Larochelle, A.; Maric, I.; Faulhaber, M.; Donahue, R.E. & Dunbar, C.E. (2010). Repetitive busulfan administration after hematopoietic stem cell gene therapy associated with a dominant HDAC7 clone in a nonhuman primate. *Human Gene Therapy*, Vol.21, No.6, (June 2010), pp. 695-703, ISSN 1525-0016
- Xue, X.; Huang, X.; Nodland, S.E.; Mátés, L.; Ma, L.; Izsvák, Z.; Ivics, Z.; LeBien, T.W.; McIvor, R.S.; Wagner, J.E. & Zhou, X. (2009). Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system. *Blood*, Vol.114, No.7, (August 2009), pp. 1319-1330, ISSN 0006-4971
- Yoshihara, H.; Arai, F.; Hosokawa, K.; Hagiwara, T.; Takubo, K.; Nakamura, Y.; Gomei, Y.; Iwasaki, H.; Matsuoka, S.; Miyamoto, K.; Miyazaki, H.; Takahashi, T. & Suda, T. (2007). Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. *Cell Stem Cell*, Vol.1, No.6, (December 2007), pp. 685-697, ISSN 1934-5909
- Yuan, Y.; Tse, K.T.; Sin, F.W.; Xue, B.; Fan, H.H.; Xie, Y. & Xie, Y. (2011). Ex vivo amplification of human hematopoietic stem and progenitor cells in an alginate three-dimensional culture system. *International Journal of Laboratory Hematology*, Vol.33, No.5, (October 2011), pp. 516-525, ISSN 1751-5521

- Yusa, K.; Zhou, L.; Li, M.A.; Bradley, A. & Craig, N.L. (2011). A hyperactive piggyBac transposase for mammalian applications. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.108, No.4, (January 2011), pp. 1531-1536, ISSN 0027-8424
- Zayed, H.; Izsvák, Z.; Walisko, O. & Ivics, Z. (2004). Development of hyperactive sleeping beauty transposon vectors by mutational analysis. *Molecular Therapy*, Vol. 9, No.2, (February 2004), pp. 292-304, ISSN 1525-0016.
- Zhang, C.C.; Kaba, M.; Ge, G.; Xie, K.; Tong, W.; Hug, C. & Lodish, H.F. (2006). Angiopoietin-like proteins stimulate ex vivo expansion of hematopoietic stem cells. *Nature Medicine*, Vol.12, No.2, (February 2006), pp. 240-245, ISSN 1078-8956
- Zhang, J.; Niu, C.; Ye, L.; Huang, H.; He, X.; Tong, W.G.; Ross, J.; Haug, J.; Johnson, T.; Feng, J.Q.; Harris, S.; Wiedemann, L.M.; Mishina, Y. & Li, L. (2003). Identification of the haematopoietic stem cell niche and control of the niche size. *Nature*, Vol.425, No.6960, (October 2003), pp. 836-841, ISSN 0028-0836
- Zhang, P.; Iwasaki-Arai, J.; Iwasaki, H.; Fenyus, M.L.; Dayaram, T.; Owens, B.M.; Shigematsu, H.; Levantini, E.; Huettner, C.S.; Lekstrom-Himes, J.A.; Akashi, K. & Tenen, D.G. (2004). Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha. *Immunity*, Vol.21, No.6, (December 2004), pp. 853-863, ISSN 1074-7613
- Zhang, X. & Roth, M.J. (2010). Antibody-directed lentiviral gene transduction in early immature hematopoietic progenitor cells. *The Journal of Gene Medicine*, Vol.12, No.12, (December 2010), pp. 945-955, ISSN 1099-498X
- Zhang, X.B.; Beard, B.C.; Beebe, K.; Storer, B.; Humphries, R.K. & Kiem, H.P. (2006). Differential effects of HOXB4 on nonhuman primate short- and long-term repopulating cells. *PLoS Medicine*, Vol.3, No.5, (May 2006), pp. e173, ISSN 1549-1277
- Zhang, X.B.; Beard, B.C.; Trobridge, G.D.; Wood, B.L.; Sale, G.E.; Sud, R.; Humphries, R.K. & Kiem H.P. (2008). High incidence of leukemia in large animals after stem cell gene therapy with a HOXB4-expressing retroviral vector. *The Journal of Clinical Investigation*, Vol.118, No.4, (April 2008), pp. 1502-1510, ISSN 0021-9738
- Zhu, J.; Zhang, Y.; Joe, G.J.; Pompetti, R. & Emerson, S.G. (2005). NF- $\kappa$ B activates multiple hematopoietic stem cell (HSC) regulatory genes and promotes HSC self-renewal. *Proceedings of the National Academy of Sciences of the United States of America*, Vol.102, No.33, (August 2005), pp. 11728-11733, ISSN 0027-8424
- Zielske, S.P.; Reese, J.S.; Lingas, K.T.; Donze, J.R. & Gerson, S.L. (2003). In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning. *The Journal of Clinical Investigation*, Vol.12, No.10, (November 2003), pp. 1561-1570, ISSN 0021-9738



## **Advances in Hematopoietic Stem Cell Research**

Edited by Dr. Rosana Pelayo

ISBN 978-953-307-930-1

Hard cover, 464 pages

**Publisher** InTech

**Published online** 27, January, 2012

**Published in print edition** January, 2012

This book provides a comprehensive overview in our understanding of the biology and therapeutic potential of hematopoietic stem cells, and is aimed at those engaged in stem cell research: undergraduate and postgraduate science students, investigators and clinicians. Starting from fundamental principles in hematopoiesis, *Advances in Hematopoietic Stem Cell Research* assemble a wealth of information relevant to central mechanisms that may regulate differentiation, and expansion of hematopoietic stem cells in normal conditions and during disease.

### **How to reference**

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Maria Savvateeva, Fedor Rozov and Alexander Belyavsky (2012). Gene Therapy of Hematopoietic and Immune Systems: Current State and Perspectives, *Advances in Hematopoietic Stem Cell Research*, Dr. Rosana Pelayo (Ed.), ISBN: 978-953-307-930-1, InTech, Available from:  
<http://www.intechopen.com/books/advances-in-hematopoietic-stem-cell-research/gene-therapy-of-hematopoietic-and-immune-systems-current-state-and-perspectives>

**INTECH**  
open science | open minds

### **InTech Europe**

University Campus STeP Ri  
Slavka Krautzeka 83/A  
51000 Rijeka, Croatia  
Phone: +385 (51) 770 447  
Fax: +385 (51) 686 166  
[www.intechopen.com](http://www.intechopen.com)

### **InTech China**

Unit 405, Office Block, Hotel Equatorial Shanghai  
No.65, Yan An Road (West), Shanghai, 200040, China  
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元  
Phone: +86-21-62489820  
Fax: +86-21-62489821

© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

IntechOpen

IntechOpen